Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Background: Initial evidence have shown the short-term efficacy of sTMS in the acute and preventive treatment of migraine. It is unknown whether this treatment approach in the long-term is effective and well tolerated in difficult-to-treat migraine. Methods: This is a prospective, single centre, open-label, real-world analysis conducted in difficult-to-treat patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM) with and without medication overuse headache (MOH), who were exposed to sTMS therapy. Patients responding to a three-month sTMS treatment, continued the treatment and were assessed again at month 12. The cut-off outcome for treatment continuation was reduction in the monthly moderate to severe headache days (MHD) of at least 30% (headache frequency responders) and/or a ≥ 4-point reduction in headache disability using the Headache Impact test-6 (HIT-6) (headache disability responders). Results: One hundred fifty-three patients were included in the analysis (F:M = 126:27, median age 43, IQR 32.3–56.8). At month 3, 93 out of 153 patients (60%) were responders to treatment. Compared to baseline, the median reduction in monthly headache days (MHD) for all patients at month 3 was 5.0 days, from 18.0 (IQR: 12.0–26.0) to 13.0 days (IQR: 5.75–24.0) (P = 0.002,r = − 0.29) and the median reduction in monthly migraine days (MMD) was 4.0 days, from 13.0 (IQR: 8.75–22.0) to 9.0 (IQR: 4.0–15.25) (P = 0.002,r = − 0.29). Sixty-nine out of 153 patients (45%) reported a sustained response to sTMS treatment at month 12. The percentage of patients with MOH was reduced from 52% (N = 79/153) at baseline to 19% (N = 29/153) at month 3, to 8% (N = 7/87) at month 12. There was an overall median 4-point reduction in HIT-6 score, from 66 (IQR: 64–69) at baseline to 62 at month 3 (IQR: 56–65) (P < 0.001,r = − 0.51). A total of 35 mild/moderate adverse events were reported by 23 patients (15%). One patient stopped sTMS treatment due to scalp sensitivity. Conclusions: This open label analysis suggests that sTMS may be an effective, well-tolerated treatment option for the long-term prevention of difficult-to-treat CM and HFEM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In migraines, especially with aura, single-pulse TMS studies report significant reductions in monthly headache days, sustained up to 12 months in difficult-to-treat cohorts [107,108,109,110,111,119,120,121,122], while results for chronic migraine remain inconclusive [117,122].”
From The Heart’s Electromagnetic Field in Emotions, Empathy and Human Connection: Biosensor-Derived Insights into Heart–Brain Axis Mechanisms and a Basis for Novel BioMagnetoTherapies (2026) · cites this paper as [122]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Aurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., Diener, H., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364676 · Cited by 1,047
Diener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., Silberstein, S., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364677 · Cited by 960
Fremanezumab for the Preventive Treatment of Chronic Migraine
Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709038 · Cited by 792
Tepper, S., Ashina, M., Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D., & Lenz, R. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30083-2 · Cited by 722
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
Dodick, D. W., Ashina, M., Brandes, J. L., Kudrow, D., Lanteri-Minet, M., Osipova, V., Palmer, K., Picard, H., Mikol, D. D., & Lenz, R. A. (2018) · Cephalalgia · doi:10.1177/0333102418759786 · Cited by 566 · cited 1×
“Furthermore, clinical trials data show a meaningful response rate of about 40–50% in CM and difficult-to-treat CM patients [9], highlighting the still unresolved unmet need in migraine management.”
BackgroundGalcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Detke, H. C., Goadsby, P. J., Wang, S., Friedman, D. I., Selzler, K. J., & Aurora, S. K. (2018) · Neurology · doi:10.1212/wnl.0000000000006640 · Cited by 563
Diener, H.-C., Bussone, G., Oene, J. V., Lahaye, M., Schwalen, S., & Goadsby, P. (2007) · Cephalalgia · doi:10.1111/j.1468-2982.2007.01326.x · Cited by 561 · cited 1×
“In CM preventive treatment trials, a significant placebo response is often noted [43, 44].”
BackgroundInternational Classification of Headache Disorders
Olesen, J. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30085-1 · Cited by 544
Lipton, R. B., Dodick, D. W., Silberstein, S. D., Saper, J. R., Aurora, S. K., Pearlman, S. H., Fischell, R. E., Ruppel, P. L., & Goadsby, P. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70054-5 · Cited by 465 · cited 1×
“In a sham-control clinical trial, sTMS administered over the occipital cortex has shown to be superior to sham as an abortive treatment in migraine with aura patients [16].”
Background
Research works printed but not linked: 2
- Lambru G, Lanteri-Minet M (2019) Neuromodulation in headache and facial pain management: principles. Springer Nature, Rationale and Clinical Data
- Ltd BC (2022) editorial policies biomedcentral [Available from: https://www.biomedcentral.com/getpublished/editorial-policies#duplicate+publication
Cited by
Migraine: from pathophysiology to treatment
Puledda, F., Silva, E. M., Suwanlaong, K., & Goadsby, P. J. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11706-1 · Cited by 187
“The efficacy of sTMS in migraine prevention has also been shown in difficult-to-treat patients [206].”
BackgroundResistant and refractory migraine: clinical presentation, pathophysiology, and management
Ornello, R., Andreou, A. P., Matteis, E. D., Jürgens, T. P., Minen, M. T., & Sacco, S. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104943 · Cited by 80
Self-citationMigraine with and without aura—two distinct entities? A narrative review
Grodzka, O., Dzagoevi, K., Rees, T. A., Cabral, G., Chądzyński, P. R., Antonio, S. D., Sochań, P., MaassenVanDenBrink, A., & Lampl, C. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01998-1 · Cited by 40
“Moreover, studies suggest that sTMS can be a valuable option in the therapy of both episodic and chronic migraine regardless of the aura presence [180, 181].”
Yuan, H., Orr, S. L., Al‐Karagholi, M. A., Ashina, M., Cohen, F., Diener, H., Dodick, D. W., Jensen, R., Marmura, M. J., Martinelli, D., et al. (2025) · Cephalalgia · doi:10.1177/03331024251388377 · Cited by 24
Spreading depolarization as a therapeutic target in migraine
Harriott, A. M., & Ayata, C. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01128-0 · Cited by 24
“Two clinical studies of daily sTMS suggested beneficial effects in migraine, but these studies were not randomized, blinded, placebo-controlled trials 222,223 .”
Metadata
- Authors
- Lloyd, J. O., Hill, B., Murphy, M., Al-Kaisy, A., Andreou, A. P., & Lambru, G.
- Affiliations
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Corresponding author
- Lambru, G.
- Venue
- The Journal of Headache and Pain
- Published
- 2022-06-06
- Volume
- 23
- Issue
- 1
- Pages
- 63-63
- ISSN
- 1129-2369 (ISSN-L)
- 1129-2377
- PMC
- PMC9169440
- OpenAlex
- W4281650061
- Cited by
- 21
- References
- 42
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 2 · 2023: 4 · 2022: 1
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- The Journal of Headache and Pain (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Dentistry › Oral Surgery › Temporomandibular Joint Disorders
- Keywords
- single-pulse transcranial magnetic stimulation, migraine prophylaxis, chronic migraine, medication overuse headache, episodic migraine, long-term treatment efficacy, sustained treatment response, headache-related disability, monthly headache days, treatment tolerability, adverse events, real-world evidence, HIT-6, migraine-specific quality of life
- MeSH terms
- Adult, Headache, Humans, Migraine Disorders, Prospective Studies, Treatment Outcome, Transcranial Magnetic Stimulation, Headache Disorders, Secondary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis. https://app.cochat.ai/papers/10.1186/s10194-022-01428-6
- The paper
- Lloyd, J. O., Hill, B., Murphy, M., Al-Kaisy, A., Andreou, A. P., & Lambru, G. (2022). Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis. The Journal of Headache and Pain. https://doi.org/10.1186/s10194-022-01428-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


